Amarin reported $3K in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 645M 69M Mar/2026
Alnylam Pharmaceuticals USD 82.05M 12.76M Jun/2026
Amarin USD 3K 5K Dec/2024
AstraZeneca USD 340M 144M Jun/2026
BioCryst Pharmaceuticals USD 21.71M 7.58M Jun/2026
DBV Technologies USD 461K 323.71K Mar/2025
GlaxoSmithKline GBP 121M 46M Jun/2026
Halozyme Therapeutics USD 5.59M 80K Jun/2026
Heron Therapeutics USD 600K 100K Dec/2024
Ionis Pharmaceuticals USD 18M 1000K Jun/2026
Nektar Therapeutics USD 7.94M 1.83M Mar/2026
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 462M 119M Jun/2026